All Eyes On CTIX, Busy Days Ahead For KURA, Make-or-Break Events Await CYNA

(RTTNews) - aTyr Pharma Inc. (LIFE) has completed enrollment of its phase 1b/2 trial of Resolaris in patients with limb-girdle muscular dystrophy 2B or facioscapulohumeral muscular dystrophy. Data from this trial are expected to be announced in the fourth quarter of this year.

The company reported positive results from its first phase 1b/2 trial of Resolaris in adult FSHD (facioscapulohumeral muscular dystrophy) patients.

LIFE closed Wednesday's trading at $3.01, down 4.14%.

Empliciti, developed by Bristol-Myers Squibb (BMY) and AbbVie (ABBV), has been approved in the European Union for the treatment of multiple myeloma as combination therapy with Revlimid and dexamethasone in patients who have received at least one prior therapy.

Empliciti in combination with Revlimid and dexamethasone was approved by the FDA last November.

GlobalData estimates that Empliciti could reach peak sales of $4.2 billion in 2022.

BMY closed Wednesday's trading at $70.81, down 1.01%.

The clinical database of Cellceutix Corp.'s (CTIX.OB) phase II clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week.

The top-line data from the study is expected to be released approximately one week after the blind is removed.

CTIX.OB closed Wednesday's trading at $1.59, down 2.45%.

Cynapsus Therapeutics Inc. (CYNA) has a number of milestones to achieve in the coming months, which can have a significant impact on its stock price.

Top-line data from a phase III efficacy study of APL-130277 for the acute treatment of OFF episodes in patients with Parkinson's disease are expected in the second or third quarter of 2016.

Another phase III study to examine the long-term safety, tolerability and efficacy of APL-130277 for the acute treatment of OFF episodes in patients with Parkinson's disease is also underway, and top-line data are expected in the fourth quarter of 2016 or the first quarter of 2017.

If all goes well as planned, an NDA for APL-130277 is expected to be submitted near the end of 2016 or in early 2017.

CYNA closed Wednesday's trading at $12.39, down 0.48%.

Kura Oncology Inc. (KURA) is preparing for a busy second half of the year.

The company's phase II clinical trials of Tipifarnib in patients with HRAS mutant solid tumors, relapsed or refractory peripheral T-cell lymphoma and lower risk myelodysplastic syndromes are underway.

Topline data from the phase II trial for Tipifarnib in HRAS mutant solid tumors is anticipated in the second half of 2016.

The company has plans to initiate a phase II clinical trial for Tipifarnib in patients with chronic myelomonocytic leukemia in the second half of 2016.

Kura began trading on the Nasdaq on November 5, 2015, offering its shares at a price of $8.00 each. The stock closed Wednesday's trading at $3.09, up 9.96%.